Alefacept for severe alopecia areata: A randomized, double-blind, placebo-controlled study

Archives of Dermatology

Volumn 145, Issue 11, 2009, Pages 1262-1266

  Strober, Bruce E ^a   Menon, Kavita ^a   McMichael, Amy ^b   Hordinsky, Maria ^c   Krueger, Gerald ^d   Panko, Jackie ^d   Siu, Kimberly ^a   Lustgarten, Jonathan L ^e   Ross, Elizabeth K ^f   Shapiro, Jerry ^a,g  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f Dermatology and Laser Center NW ^*  (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; PLACEBO;

ADULT; ALOPECIA AREATA; ARTHROPATHY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INFLUENZA; MALE; MULTICENTER STUDY; NOSE CONGESTION; PRIORITY JOURNAL; SCORING SYSTEM; SELF EVALUATION; SEVERITY OF ALOPECIA TOOL; SIDE EFFECT; TREATMENT DURATION; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION;

ACADEMIC MEDICAL CENTERS; ADOLESCENT; ADULT; AGED; ALOPECIA AREATA; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEW YORK CITY; PROBABILITY; RECOMBINANT FUSION PROTEINS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 72749106793     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.264     Document Type: Article

References (20)

1. Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A. Alopecia areata. Int J Dermatol. 2007;46(2):121-131.
2. Dudda-Subramanya R, Alexis AF, Siu K, Sinha AA. Alopecia areata: genetic complexity underlies clinical heterogeneity. Eur J Dermatol. 2007;17(5):367-374. (Pubitemid 47425901)
3. Price VH, Hordinsky MK, Olsen EA, et al. Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J Am Acad Dermatol. 2008;58(3):395-402.
4. McDonagh AJ, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol. 2002;27(5):405-409.
5. Lu W, Shapiro J, Yu M, et al. Alopecia areata: pathogenesis and potential for therapy. Expert Rev Mol Med. 2006;8(14):1-19. (Pubitemid 43923144)
6. Christoph T, Müller-Röver S, Audring H, et al. The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol. 2000;142(5):862-873. (Pubitemid 30304594)
7. Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol. 2003;139(12):1555-1559.
8. Gilhar A, Ullmann Y, Berkutzki T, Assy B, Kalish RS. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest. 1998;101(1):62-67. (Pubitemid 28058903)
9. Strober BE, Siu K, Alexis AF, et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol. 2005;52(6):1082-1084. (Pubitemid 40732553)
10. Amevive [package insert]. Cambridge, MA: Biogen Inc; 2003.
11. Strober BE, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther. 2007;20(4):270-276. (Pubitemid 350030789)
12. Vaishnaw AK, TenHoor CN. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn. 2002;29(5-6):415-426.
13. Gottlieb AB. Alefacept is well tolerated in patients with chronic plaque psoriasis. J Cutan Med Surg. 2004;8(suppl 2):14-19. (Pubitemid 40228480)
14. Lebwohl M, Christophers E, Langley RG, Ortonne JP, Roberts J, Griffiths CE; Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139(6):719-727. (Pubitemid 36705938)
15. Heffernan MP, Hurley MY, Martin KS, Smith DI, Anadkat MJ. Alefacept for alopecia areata. Arch Dermatol. 2005;141(12):1513-1516.
16. Bui K, Polisetty S, Gilchrist H, Jackson SM, Frederic J. Successful treatment of alopecia universalis with alefacept: a case report and review of the literature. Cutis. 2008;81(5):431-434.
17. Olsen E, Hordinsky M, McDonald-Hull S, et al; National Alopecia Areata Foundation. Alopecia areata investigational assessment guidelines. J Am Acad Dermatol. 1999;40(2, pt 1):242-246.
18. Scheinfeld N. Alefacept: a safety profile. Expert Opin Drug Saf. 2005;4(6):975-985.
19. McElwee KJ, Freyschmidt-Paul P, Zöller M, Hoffmann R. Alopecia areata susceptibility in rodent models. J Investig Dermatol Symp Proc. 2003;8(2):182-187. (Pubitemid 37222827)
20. Price VH. Therapy of alopecia areata: on the cusp and in the future. J Investig Dermatol Symp Proc. 2003;8(2):207-211.